rituximab vasculitis ANCA
Selected indexed studies
- Rituximab versus cyclophosphamide for ANCA-associated vasculitis. (N Engl J Med, 2010) [PMID:20647199]
- Diagnosis and management of ANCA-associated vasculitis. (Lancet, 2024) [PMID:38368016]
- EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. (Ann Rheum Dis, 2024) [PMID:36927642]
_Worker-drafted node — pending editorial review._
Connections
rituximab vasculitis ANCA is a side effect of
Sources
- Obinutuzumab as treatment for ANCA-associated vasculitis. (2022) pubmed
- EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. (2024) pubmed
- Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial. (2023) pubmed
- Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). (2018) pubmed
- Efficacy and safety of avacopan in patients with ANCA-associated vasculitis receiving rituximab in a randomised trial. (2024) pubmed
- Rituximab versus cyclophosphamide for ANCA-associated vasculitis. (2010) pubmed
- Diagnosis and management of ANCA-associated vasculitis. (2024) pubmed
- Rituximab treatment of ANCA-associated vasculitis. (2020) pubmed
- Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. (2014) pubmed
- ANCA-Associated Vasculitis: Core Curriculum 2020. (2020) pubmed